MA44059A - Antigènes du virus de l'immunodéficience humaine, vecteurs, compositions, et leurs procédés d'utilisation - Google Patents

Antigènes du virus de l'immunodéficience humaine, vecteurs, compositions, et leurs procédés d'utilisation

Info

Publication number
MA44059A
MA44059A MA044059A MA44059A MA44059A MA 44059 A MA44059 A MA 44059A MA 044059 A MA044059 A MA 044059A MA 44059 A MA44059 A MA 44059A MA 44059 A MA44059 A MA 44059A
Authority
MA
Morocco
Prior art keywords
compositions
methods
vectors
immunodeficiency virus
human immunodeficiency
Prior art date
Application number
MA044059A
Other languages
English (en)
Other versions
MA44059B1 (fr
Inventor
Johannes Petrus Maria Langedijk
Original Assignee
Janssen Vaccines & Prevention Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Vaccines & Prevention Bv filed Critical Janssen Vaccines & Prevention Bv
Publication of MA44059A publication Critical patent/MA44059A/fr
Publication of MA44059B1 publication Critical patent/MA44059B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • C07K14/162—HIV-1 ; HIV-2 env, e.g. gp160, gp110/120, gp41, V3, peptid T, CD4-Binding site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des protéines d'enveloppe du vih synthétiques, des vecteurs et des compositions associés, ainsi que des procédés permettant d'induire une immunité protectrice contre une infection par le virus de l'immunodéficience humaine (vih). Des vecteurs d'expression virale codant les protéines d'enveloppe du vih synthétiques peuvent être utilisés dans des vaccins pour améliorer l'immunité protectrice contre le vih.
MA44059A 2015-12-15 2016-12-15 Antigènes du virus de l'immunodéficience humaine, vecteurs, compositions, et leurs procédés d'utilisation MA44059B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15200138 2015-12-15
EP16194124 2016-10-17
PCT/EP2016/081159 WO2017102929A1 (fr) 2015-12-15 2016-12-15 Antigènes du virus de l'immunodéficience humaine, vecteurs, compositions, et leurs procédés d'utilisation

Publications (2)

Publication Number Publication Date
MA44059A true MA44059A (fr) 2018-10-24
MA44059B1 MA44059B1 (fr) 2019-11-29

Family

ID=57737697

Family Applications (3)

Application Number Title Priority Date Filing Date
MA055825A MA55825A (fr) 2015-12-15 2016-12-15 Antigènes, vecteurs, compositions du virus de l'immunodéficience humaine et leurs procédés d'utilisation
MA47522A MA47522B1 (fr) 2015-12-15 2016-12-15 Antigènes, vecteurs, compositions du virus de l'immunodéficience humaine et leurs procédés d'utilisation
MA44059A MA44059B1 (fr) 2015-12-15 2016-12-15 Antigènes du virus de l'immunodéficience humaine, vecteurs, compositions, et leurs procédés d'utilisation

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MA055825A MA55825A (fr) 2015-12-15 2016-12-15 Antigènes, vecteurs, compositions du virus de l'immunodéficience humaine et leurs procédés d'utilisation
MA47522A MA47522B1 (fr) 2015-12-15 2016-12-15 Antigènes, vecteurs, compositions du virus de l'immunodéficience humaine et leurs procédés d'utilisation

Country Status (30)

Country Link
US (3) US10369214B2 (fr)
EP (3) EP3390430B1 (fr)
JP (2) JP6510149B2 (fr)
KR (1) KR102960814B1 (fr)
CN (2) CN108368157B (fr)
AU (2) AU2016369326B2 (fr)
BR (1) BR112018011122A2 (fr)
CA (1) CA3008542C (fr)
CY (2) CY1122705T1 (fr)
DK (2) DK3584252T3 (fr)
EA (1) EA038974B1 (fr)
ES (2) ES2753854T3 (fr)
HR (2) HRP20211566T1 (fr)
HU (2) HUE045993T2 (fr)
IL (1) IL259942B2 (fr)
LT (2) LT3584252T (fr)
MA (3) MA55825A (fr)
MD (2) MD3584252T2 (fr)
ME (1) ME03545B (fr)
MX (2) MX383507B (fr)
PH (1) PH12018501047A1 (fr)
PL (2) PL3390430T3 (fr)
PT (1) PT3390430T (fr)
RS (2) RS59447B1 (fr)
SG (2) SG10202109457RA (fr)
SI (2) SI3584252T1 (fr)
SM (2) SMT201900629T1 (fr)
TW (2) TWI792091B (fr)
WO (1) WO2017102929A1 (fr)
ZA (1) ZA201803978B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA40765B1 (fr) 2014-09-26 2021-04-30 Beth Israel Deaconess Medical Ct Inc Méthodes et compositions d'induction d'une immunité protectrice contre l'infection par le virus de l'immunodéficience humaine
MA40783A (fr) 2014-10-03 2017-08-08 Los Alamos Nat Security Llc Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population
EP3031923A1 (fr) * 2014-12-11 2016-06-15 Institut Pasteur Composition immunogène contre l'encéphalite japonaise à base de vecteurs lentiviraux
PL3390430T3 (pl) 2015-12-15 2020-03-31 Janssen Vaccines & Prevention B.V. Antygeny ludzkiego wirusa niedoboru odporności, wektory, kompozycje i sposoby ich zastosowania
EA201892735A1 (ru) 2016-06-16 2019-05-31 Янссен Вэксинс Энд Превеншн Б.В. Состав вакцины против hiv
CA3035759A1 (fr) 2016-09-02 2018-03-08 Janssen Vaccines & Prevention B.V. Procedes pour induire une reponse immunitaire contre une infection par le virus de l'immunodeficience humaine chez des sujets subissant un traitement antiretroviral
JP7178344B2 (ja) 2016-09-15 2022-11-25 ヤンセン ファッシンズ アンド プリベンション ベーフェー 三量体安定化ｈｉｖエンベロープタンパク質変異
BR112019026126A2 (pt) 2017-06-15 2020-06-30 Janssen Vaccines & Prevention B.V. vetores de poxvírus que codificam antígenos do hiv e métodos de uso dos mesmos
MY200554A (en) * 2017-07-19 2024-01-03 Janssen Vaccines & Prevention Bv Trimer stabilizing hiv envelope protein mutations
US20190083620A1 (en) 2017-09-18 2019-03-21 Janssen Vaccines & Prevention B.V. Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
AU2018366480C1 (en) * 2017-11-17 2024-02-01 Grifols Diagnostic Solutions Inc. Novel mammalian expressed human immunodeficiency virus envelope protein antigens
CN114269363A (zh) * 2019-04-17 2022-04-01 威斯达研究所 用于hiv疫苗应用的复制缺陷型腺病毒载体
TW202110476A (zh) 2019-05-22 2021-03-16 荷蘭商傑森疫苗防護公司 於接受抗反轉錄病毒治療之個體中誘發抗人類免疫缺乏病毒感染之免疫反應的方法
CA3159907A1 (fr) 2019-11-07 2021-05-14 Janssen Vaccines & Prevention B.V. Purification de proteines
CA3182703A1 (fr) 2020-05-12 2021-11-18 Janssen Vaccines & Prevention B.V. Administration de vecteurs adenoviraux homologues
WO2021249011A1 (fr) * 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Compositions de vaccin contre le vih, procédés et utilisations associées
WO2022006095A2 (fr) * 2020-06-29 2022-01-06 Duke University Enveloppes mosaïques du vih-1 pour induire des réponses d'adcc
WO2022084333A1 (fr) 2020-10-20 2022-04-28 Janssen Vaccines & Prevention B.V. Régimes de vaccin contre le vih
KR20230150269A (ko) 2021-02-23 2023-10-30 얀센 백신스 앤드 프리벤션 비.브이. Hiv 외피 단백질 돌연변이를 안정화시키는 삼량체
US20230000973A1 (en) * 2021-06-25 2023-01-05 Janssen Vaccines & Prevention B.V. Combinations of Vaccines and Neutralizing Antibodies for Treating Human Immunodeficiency Virus Infection in Subjects Undergoing Antiretroviral Treatment
WO2023242155A1 (fr) 2022-06-14 2023-12-21 Janssen Vaccines & Prevention B.V. Compositions et procédés pour le diagnostic d'une infection par le vih

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
CA1341245C (fr) 1988-01-12 2001-06-05 F. Hoffmann-La Roche Ag Virus recombinant de la vaccine derive du virus modifie ankara
US5298416A (en) 1989-01-18 1994-03-29 British Technology Group Ltd. Attenuated polioviruses
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
UA68327C2 (en) 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
US6479258B1 (en) 1995-12-07 2002-11-12 Diversa Corporation Non-stochastic generation of genetic vaccines
US5741492A (en) * 1996-01-23 1998-04-21 St. Jude Children's Research Hospital Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses
US6083716A (en) 1996-09-06 2000-07-04 The Trustees Of The University Of Pennsylvania Chimpanzee adenovirus vectors
US5761893A (en) 1996-10-22 1998-06-09 Lofquist Welding, Inc. Crop saving attachment for the snouts of combines
ATE519854T1 (de) 1999-05-17 2011-08-15 Crucell Holland Bv Rekombinantes adenovirus auf basis von serotyp 48 (ad48).
WO2003104467A1 (fr) 2002-04-25 2003-12-18 Crucell Holland B.V. Moyens et procede de production de vecteurs d'adenovirus
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6710173B1 (en) 1999-06-25 2004-03-23 Progenics Pharmaceuticals, Inc. Stabilized viral envelope proteins and uses thereof
WO2001019958A2 (fr) 1999-09-17 2001-03-22 Dana-Farber Cancer Institute, Inc. Trimeres stabilises solubles de glycoproteines
HU230198B1 (hu) 2000-11-23 2015-10-28 Bavarian Nordic A/S Módosított Vacciniavírus Ankara-variáns
CA2785699A1 (fr) * 2001-07-05 2003-01-16 Novartis Vaccines And Diagnostics, Inc. Polynucleotides codant des polypeptides de type c du vih antigeniques, polypeptides et leurs utilisations
EP1409694A4 (fr) * 2001-07-05 2006-02-08 Chiron Corp Polynucleotides codant pour des polypeptides antigeniques du vih de sous-type b et/ou de sous-type c, polypeptides et leurs utilisations
EP1456230A2 (fr) 2001-12-04 2004-09-15 Bavarian Nordic A/S Vaccin a sous-unite de ns1 de flavivirus
CA2478508C (fr) 2002-04-25 2013-07-02 Crucell Holland B.V. Vecteurs adenoviraux stables et techniques de propagation de ces vecteurs
AU2003291402A1 (en) 2002-11-07 2004-06-03 Beth Israel Deaconess Medical Center MIP-1Alpha AND GM-CSF AS ADJUVANTS OF IMMUNE RESPONSE
US7901690B2 (en) 2002-12-03 2011-03-08 University Of Massachusetts Polyvalent, primary HIV-1 glycoprotein DNA vaccines and vaccination methods
WO2004087201A2 (fr) 2003-03-28 2004-10-14 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mva exprimant des genes modifies enveloppe, gag et pol du vih
WO2005027840A2 (fr) 2003-09-15 2005-03-31 Chiron Corporation Approches combinees pour produire des reponses immunitaires
WO2005035555A1 (fr) 2003-10-10 2005-04-21 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeres env de hiv/siv avec capacite de promotion de la trimerisation de maintien de cibles d'anticorps neutralisants
WO2005052119A2 (fr) 2003-11-19 2005-06-09 Beth Israel Deaconess Medical Center Adjuvants de la reponse immunitaire
JP4814800B2 (ja) 2004-01-23 2011-11-16 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー チンパンジーアデノウイルスワクチン担体
WO2005110492A2 (fr) * 2004-04-12 2005-11-24 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Méthode pour utiliser les vecteurs adénovirals amener une réponse immunitaire
WO2006002079A2 (fr) 2004-06-15 2006-01-05 Progenics Pharmaceuticals, Inc. Anticorps de neutralisation du vih-1 elicites par un complexe trimerique de glycoproteines d'enveloppe du vih-1
EP2397490B1 (fr) * 2004-07-16 2013-09-04 THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Constructions de vaccins et combinaisons de vaccins conçus pour améliorer l'étendue de la réponse immunitaire de différentes souches et variantes du VIH
WO2006026667A2 (fr) * 2004-08-27 2006-03-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Virus mva de recombinaison exprimant les genes modifies env, gag et pol du vih variantes a/g, b, et c
US7741099B2 (en) 2004-10-13 2010-06-22 Beth Israel Deaconess Medical Center Inc. Adenoviral vectors and uses thereof
CN101588813A (zh) * 2005-04-12 2009-11-25 杜克大学 诱导人类免疫缺陷病毒的中和抗体的方法
US20100221241A1 (en) 2005-07-06 2010-09-02 University Of Maryland Biotechnology Institute Constrained hiv envelope-based immunogen that simultaneously presents receptor and coreceptor binding sites
US8119140B2 (en) 2005-08-23 2012-02-21 Los Alamos Security, LLC Immunogenic compositions comprising human immunodeficiency virus (HIV) mosaic Nef proteins
WO2007104792A2 (fr) 2006-03-16 2007-09-20 Crucell Holland B.V. Adénovirus recombinés basés sur les sérotypes 26 et 48 et utilisation de ceux-ci
EP2040747A4 (fr) 2006-06-19 2010-08-25 Progenics Pharm Inc Protéines env vih trimériques solubles stabilisées et leurs utilisations
EP2073840A4 (fr) 2006-10-23 2010-10-27 Progenics Pharm Inc Polypeptides d'enveloppe gp140 modifiés en provenance d'isolats du vih-1, compositions, complexes trimériques et utilisations de ceux-ci
US20080279879A1 (en) 2006-11-17 2008-11-13 New York University INDUCTION OF BROADLY REACTIVE NEUTRALIZING ANTIBODIES BY FOCUSING THE IMMUNE RESPONSE ON V3 EPITOPES OF THE HIV-1 gp120 ENVELOPE
CN103550764A (zh) 2007-03-02 2014-02-05 葛兰素史密丝克莱恩生物有限公司 疫苗组合物及其在刺激免疫反应中的用途
SMT202000101T1 (it) 2008-10-10 2020-03-13 Childrens Medical Center Vaccino con trimero di env di hiv-1 stabilizzato biochimicamente
PL2358757T3 (pl) 2008-11-18 2019-02-28 Beth Israel Deaconess Medical Center Szczepionki antywirusowe o ulepszonej immunogenności komórkowej
WO2010085984A1 (fr) 2009-02-02 2010-08-05 Okairos Ag Séquences d'acide nucléique et d'acides aminés d'adénovirus simiens, vecteurs les contenant et leurs utilisations
HUE039908T2 (hu) 2009-02-02 2019-02-28 Glaxosmithkline Biologicals Sa Majom adenovírusból származó nukleinsav- és aminosav-szekvenciák, azt tartalmazó vektorok és alkalmazásuk
WO2010096561A1 (fr) 2009-02-18 2010-08-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Protéines gag du vih/vis de synthèse et leurs utilisations
WO2011082087A2 (fr) 2010-01-04 2011-07-07 Kj Biosciences, Llc Protéines de fusion avec des dps destinées à être utilisées dans des vaccins et des produits de diagnostic
NZ600629A (en) 2010-01-28 2014-12-24 Bavarian Nordic As Vaccinia virus mutants containing the major genomic deletions of mva
CA3201524C (fr) 2010-08-31 2026-01-13 International Aids Vaccine Initiative Anticorps neutralisants anti-virus de l'immunodeficience humaine (vih)
KR101879892B1 (ko) 2010-12-14 2018-08-17 더 거버먼트 오브 더 유나이티드 스테이츠 오브 아메리카 에즈 레프리젠티드 바이 더 세크러테리 오브 더 디파트먼트 오브 헬스 앤드 휴먼 서비시즈 아데노바이러스 혈청형 26 및 혈청형 35 필로바일러스 백신
JP6407714B2 (ja) * 2011-04-25 2018-10-17 アドヴァンスド バイオサイエンス ラボラトリーズ インコーポレイテッド 短縮型ｈｉｖエンベロープタンパク質（ｅｎｖ）、前記に関連する方法及び組成物
US20140348791A1 (en) 2011-09-09 2014-11-27 Beth Israel Deaconess Medical Center, Inc. Modified adenoviral vectors and methods of treatment using same
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
WO2013040766A1 (fr) * 2011-09-21 2013-03-28 中国疾病预防控制中心性病艾滋病预防控制中心 Procédé et vaccin pouvant induire une réponse immunitaire à large spectre contre le vih
WO2013055908A1 (fr) 2011-10-12 2013-04-18 The Scripps Research Institute Mini boucle v3 de gp120 du vih-1 et ses utilisations
US9683268B2 (en) 2012-09-19 2017-06-20 Beth Israel Deaconess Viruses associated with immunodeficiency and enteropathy and methods using same
CA2891349C (fr) 2012-11-16 2023-07-18 Beth Israel Deaconess Medical Center, Inc. Adenovirus recombinants et leur utilisation
WO2014107744A1 (fr) 2013-01-07 2014-07-10 Beth Israel Deaconess Medical Center, Inc. Vaccins de trimère d'enveloppe (env) de virus d'immunodéficience humaine (vih) stabilisés et procédés d'utilisation de ceux-ci
US10248758B2 (en) 2013-02-07 2019-04-02 University Of Washington Through Its Center For Commercialization Self-assembling protein nanostructures
US9624510B2 (en) * 2013-03-01 2017-04-18 The Wistar Institute Adenoviral vectors comprising partial deletions of E3
WO2015048770A2 (fr) 2013-09-30 2015-04-02 Beth Israel Deaconess Medical Center, Inc. Traitements par anticorps pour le virus de l'immunodéficience humaine (vih)
EP3666790A1 (fr) * 2013-10-04 2020-06-17 Beth Israel Deaconess Medical Center, Inc. Caccins de trimères d'enveloppe (env) de clade c du virus de l'immunodéficience humaine (vih) stabilisés et procédés d'utilisation de ceux-ci
JP2017507672A (ja) * 2014-02-28 2017-03-23 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 複製型組み換えアデノウイルスベクター、組成物およびこれらの使用方法
US10400015B2 (en) 2014-09-04 2019-09-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant HIV-1 envelope proteins and their use
MA40765B1 (fr) 2014-09-26 2021-04-30 Beth Israel Deaconess Medical Ct Inc Méthodes et compositions d'induction d'une immunité protectrice contre l'infection par le virus de l'immunodéficience humaine
US9630994B2 (en) 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
EP3271729B1 (fr) * 2015-03-18 2020-09-23 Janssen Vaccines & Prevention B.V. Essais pour des systèmes d'expression recombinants
PL3390430T3 (pl) 2015-12-15 2020-03-31 Janssen Vaccines & Prevention B.V. Antygeny ludzkiego wirusa niedoboru odporności, wektory, kompozycje i sposoby ich zastosowania
EA201892735A1 (ru) 2016-06-16 2019-05-31 Янссен Вэксинс Энд Превеншн Б.В. Состав вакцины против hiv
CA3035759A1 (fr) 2016-09-02 2018-03-08 Janssen Vaccines & Prevention B.V. Procedes pour induire une reponse immunitaire contre une infection par le virus de l'immunodeficience humaine chez des sujets subissant un traitement antiretroviral
JP7178344B2 (ja) 2016-09-15 2022-11-25 ヤンセン ファッシンズ アンド プリベンション ベーフェー 三量体安定化ｈｉｖエンベロープタンパク質変異
DE102018124348A1 (de) 2018-10-02 2020-04-02 Haver & Boecker Ohg Füllkasten und Verfahren zum Füllen von Gebinden

Also Published As

Publication number Publication date
EP3584252B1 (fr) 2021-08-25
ZA201803978B (en) 2021-05-26
KR102960814B1 (ko) 2026-05-04
US10369214B2 (en) 2019-08-06
TWI792091B (zh) 2023-02-11
MX383507B (es) 2025-03-14
MX2018007198A (es) 2018-08-01
CA3008542A1 (fr) 2017-06-22
AU2016369326B2 (en) 2019-02-21
MX2021006931A (es) 2021-07-07
US11896663B2 (en) 2024-02-13
JP6959289B2 (ja) 2021-11-02
MA55825A (fr) 2022-03-09
DK3584252T3 (da) 2021-11-15
TWI707039B (zh) 2020-10-11
IL259942A (en) 2018-07-31
PL3390430T3 (pl) 2020-03-31
EP3964569A1 (fr) 2022-03-09
TW202106701A (zh) 2021-02-16
IL259942B (en) 2022-12-01
IL259942B2 (en) 2023-04-01
EP3584252A1 (fr) 2019-12-25
US20210220468A1 (en) 2021-07-22
EP3390430A1 (fr) 2018-10-24
AU2019203468A1 (en) 2019-06-06
TW201734210A (zh) 2017-10-01
MD3390430T2 (ro) 2019-12-31
SG10202109457RA (en) 2021-10-28
AU2016369326A1 (en) 2018-06-07
JP2019146574A (ja) 2019-09-05
SI3390430T1 (sl) 2019-12-31
ME03545B (fr) 2020-07-20
SI3584252T1 (sl) 2021-11-30
SMT202100623T1 (it) 2022-01-10
DK3390430T3 (da) 2019-11-18
PL3584252T3 (pl) 2022-01-10
WO2017102929A1 (fr) 2017-06-22
EP3390430B1 (fr) 2019-08-28
US20190321462A1 (en) 2019-10-24
RS62360B1 (sr) 2021-10-29
MA47522B1 (fr) 2021-11-30
SG11201804411TA (en) 2018-06-28
KR20180086207A (ko) 2018-07-30
LT3584252T (lt) 2021-09-27
JP2019505188A (ja) 2019-02-28
EA201891415A1 (ru) 2018-11-30
CN114686495A (zh) 2022-07-01
ES2898271T3 (es) 2022-03-04
JP6510149B2 (ja) 2019-05-08
SMT201900629T1 (it) 2020-01-14
MA44059B1 (fr) 2019-11-29
US10973907B2 (en) 2021-04-13
CA3008542C (fr) 2020-06-02
EA201891415A8 (ru) 2019-10-31
CN108368157A (zh) 2018-08-03
HRP20191902T1 (hr) 2020-01-24
MA47522A (fr) 2021-05-05
CY1122705T1 (el) 2021-03-12
CY1125387T1 (el) 2023-03-24
AU2019203468B2 (en) 2020-05-21
HUE055916T2 (hu) 2021-12-28
LT3390430T (lt) 2019-11-25
HRP20211566T1 (hr) 2022-03-04
CN108368157B (zh) 2022-04-15
RS59447B1 (sr) 2019-11-29
ES2753854T3 (es) 2020-04-14
PT3390430T (pt) 2019-11-20
EA038974B1 (ru) 2021-11-17
HUE045993T2 (hu) 2020-01-28
PH12018501047A1 (en) 2018-12-17
MD3584252T2 (ro) 2022-01-31
US20170165355A1 (en) 2017-06-15
BR112018011122A2 (pt) 2018-11-21

Similar Documents

Publication Publication Date Title
MA44059B1 (fr) Antigènes du virus de l'immunodéficience humaine, vecteurs, compositions, et leurs procédés d'utilisation
MA40765A (fr) Méthodes et compositions d'induction d'une immunité protectrice contre l'infection par le virus de l'immunodéficience humaine
JOP20170130A1 (ar) مركبات لمعالجة عدوى فيروس التهاب الكبد الوبائي b
EA201891186A1 (ru) Антитела, нейтрализующие вирус иммунодефицита человека
MA52645B1 (fr) Vaccins contre le virus respiratoire
EP2983686A4 (fr) Vaccins de trimère d'enveloppe (env) de virus d'immunodéficience humaine (vih) stabilisés et procédés d'utilisation de ceux-ci
JOP20180008A1 (ar) مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b
MX2020005187A (es) Compuestos y composiciones farmaceuticas antivirales, asi como metodos de uso de los mismos.
MA43124A (fr) Souches recombinées vaccinales de listeria et leurs méthodes d'utilisation en immunothérapie anticancéreuse
AR101814A1 (es) Partícula de tipo virus flavivirus
EA201790517A1 (ru) Способы и композиции для индуцирования защитного иммунитета против филовирусной инфекции
MY190102A (en) Tolerogenic dna vaccine
EP3303370A4 (fr) Produits de construction t20 pour thérapie et/ou vaccins anti-vih (virus de l'immunodéficience humaine)
PH12017500816A1 (en) Long acting pharmaceutical compositions for hepatitis c
MX390927B (es) Partículas semejantes a virus recombinantes que utilizan la proteína gag del virus de inmunodeficiencia bovina.
PH12018500645A1 (en) Hiv antibody compositions and methods of use
MX2017006140A (es) Composiciones de accion prolongada de combinacion y métodos para hepatitis c.
WO2014152271A8 (fr) Protéines virales en tant qu'agents immunomodulateurs et composants de vaccin
EA202191862A3 (ru) Антигены вируса иммунодефицита человека, векторы, композиции и способы их применения
ES2401904R1 (es) Vectores recombinantes basados en el virus modificado de ankara (mva), con delecion en el gen c6l, como vacunas contra el vih/sida y otras enfermedades.